The Board of Directors of Prostatype Genomics AB decides on a previously communicated rights issue of units
The Board of Directors of Prostatype Genomics AB (”Prostatype Genomics” or the “Company”) has today, the 23[ ]June 2022, decided to execute an issue of units (shares and attached free-of-charge warrants) with preferential right for existing shareholders, where also the general public is able to participate (“the Rights Issue”). The decision on the Rights Issue was made with support by an authorization from the Annual General Meeting held on the 2[ ]June 2022 in accordance with the proposal made by the Board, which was communicated through a press release on the 2 May 2022. The Rights Issue